Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0249 in Adult ADHD
NCT00475735Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MK-0249 in attention deficit hyperactivity disorder (ADHD), sponsored by Merck & Co.. Started Jul 2007; status: completed.
02
Drugs
MK-0249
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00475735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475735.